GSK Of U.K. To Put $100 Million Into R&D Center For Neuroscience Center (China)
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline plans to develop a $100 million neuroscience research center in China as a key element in its global drug-development strategy. The company's research-and-development head said the intention is to have the center be responsible for all work on neuro-degenerative diseases for treating diseases such as Alzheimer's, Parkinson's and multiple sclerosis. Moncef Sioui said GSK no longer sees China as an outsourcing and cheap-labor center, but now one capable of "different science." Several other global drug firms also are eying significant R&D investments in China. (Click here for more ) "GSK In $100 Million China Push" Financial Times (U.K.) (12/13/07)